Oxaliplatin regulates myeloid-derived suppressor cell-mediated immunosuppression via downregulation of nuclear factor-κB signaling.

ABSTRACT: Myeloid-derived suppressor cells (MDSCs) represent one of the major types of immunoregulatory cells present under abnormal conditions, including cancer. These cells are characterized by their immature phenotype and suppressive effect on various immune effectors. In both human and mouse, there are two main subsets of MDSCs: polymorphonuclear (PMN)-MDSCs and mononuclear (Mo)-MDSCs. Thus, strategies to regulate MDSC-mediated immunosuppression could result in the enhancement of anticancer immune responses. Oxaliplatin, a platinum-based anticancer agent, is widely used in clinical settings. It is known to induce cell death by interfering with double-stranded DNA and interrupting its replication and transcription. In this study, we found that oxaliplatin has the potential to regulate MDSC-mediat

SUBMITTER: Kim NR 

PROVIDER: S-EPMC6346236 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature